Table 3.

Univariate and multivariate analyses of factors for OS after PSM

	Univariate analysis	Multivariate analysis
	p value	OR	95% CI	p value
Age (<75 vs. ≥75 years)	0.479
Sex (male vs. female)	0.079
Etiology (HBV vs. HCV vs. non B, C)	0.176
ALBI grade (1 vs. 2)	<0.001	0.581	0.401–0.842	<0.001
Maximum tumor diameter, mm (<30/≥30)	0.056
Number of tumors (<5/≥5)	0.167
Macrovascular invasion (yes/no)	0.046	0.715	0.488–1.045	0.083
Extrahepatic spread (yes/no)	0.001	2.140	1.528–3.004	0.001
AFP (<200 vs. ≥200 ng/mL)	<0.001	0.485	0.339–0.694	<0.001
Regimen (ATEZO/BEVA vs. LEN)	0.039	0.638	0.431–0.946	0.025

OR odds ratio, CI confidence interval, OS overall survival, ALBI, albumin-bilirubin, AFP α-fetoprotein, ATEZO/BEVA atezolizumab plus bevacizumab, LEN lenvatinib, PSM propensity score matching